Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Juan Carlos Fernández-López is active.

Publication


Featured researches published by Juan Carlos Fernández-López.


Science | 2011

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

Nicolas Stransky; Ann Marie Egloff; Aaron D. Tward; Aleksandar D. Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V. Kryukov; Michael S. Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H. Ramos; Petar Stojanov; Scott L. Carter; Douglas Voet; Maria L. Cortes; Daniel Auclair; Michael F. Berger; Gordon Saksena; Candace Guiducci; Robert C. Onofrio; Melissa Parkin; Marjorie Romkes; Joel L. Weissfeld; Raja R. Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernández-López; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla

The mutational profile of head and neck cancer is complex and may pose challenges to the development of targeted therapies. Head and neck squamous cell carcinoma (HNSCC) is a common, morbid, and frequently lethal malignancy. To uncover its mutational spectrum, we analyzed whole-exome sequencing data from 74 tumor-normal pairs. The majority exhibited a mutational profile consistent with tobacco exposure; human papillomavirus was detectable by sequencing DNA from infected tumors. In addition to identifying previously known HNSCC genes (TP53, CDKN2A, PTEN, PIK3CA, and HRAS), our analysis revealed many genes not previously implicated in this malignancy. At least 30% of cases harbored mutations in genes that regulate squamous differentiation (for example, NOTCH1, IRF6, and TP63), implicating its dysregulation as a major driver of HNSCC carcinogenesis. More generally, the results indicate the ability of large-scale sequencing to reveal fundamental tumorigenic mechanisms.


Nature | 2012

Sequence analysis of mutations and translocations across breast cancer subtypes

Shantanu Banerji; Kristian Cibulskis; Claudia Rangel-Escareño; Kristin K. Brown; Scott L. Carter; Abbie M. Frederick; Michael S. Lawrence; Andrey Sivachenko; Carrie Sougnez; Lihua Zou; Maria L. Cortes; Juan Carlos Fernández-López; Shouyong Peng; Kristin Ardlie; Daniel Auclair; Verónica Bautista-Piña; Fujiko Duke; Joshua M. Francis; Joonil Jung; Antonio Maffuz-Aziz; Robert C. Onofrio; Melissa Parkin; Nam H. Pho; Valeria Quintanar-Jurado; Alex H. Ramos; Rosa Rebollar-Vega; Sergio Rodriguez-Cuevas; Sandra Romero-Cordoba; Steven E. Schumacher; Nicolas Stransky

Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy represents a heterogeneous group of tumours with characteristic molecular features, prognosis and responses to available therapy. Recurrent somatic alterations in breast cancer have been described, including mutations and copy number alterations, notably ERBB2 amplifications, the first successful therapy target defined by a genomic aberration. Previous DNA sequencing studies of breast cancer genomes have revealed additional candidate mutations and gene rearrangements. Here we report the whole-exome sequences of DNA from 103 human breast cancers of diverse subtypes from patients in Mexico and Vietnam compared to matched-normal DNA, together with whole-genome sequences of 22 breast cancer/normal pairs. Beyond confirming recurrent somatic mutations in PIK3CA, TP53, AKT1, GATA3 and MAP3K1, we discovered recurrent mutations in the CBFB transcription factor gene and deletions of its partner RUNX1. Furthermore, we have identified a recurrent MAGI3–AKT3 fusion enriched in triple-negative breast cancer lacking oestrogen and progesterone receptors and ERBB2 expression. The MAGI3–AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Jens Lohr; Petar Stojanov; Michael S. Lawrence; Daniel Auclair; Bjoern Chapuy; Carrie Sougnez; Peter Cruz-Gordillo; Birgit Knoechel; Yan W. Asmann; Susan L. Slager; Anne J. Novak; Ahmet Dogan; Stephen M. Ansell; Brian K. Link; Lihua Zou; Joshua Gould; Gordon Saksena; Nicolas Stransky; Claudia Rangel-Escareño; Juan Carlos Fernández-López; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Enrique Hernández-Lemus; Angela Schwarz-Cruz y Celis; Ivan Imaz-Rosshandler; Akinyemi I. Ojesina; Joonil Jung; Chandra Sekhar Pedamallu; Eric S. Lander; Thomas M. Habermann

To gain insight into the genomic basis of diffuse large B-cell lymphoma (DLBCL), we performed massively parallel whole-exome sequencing of 55 primary tumor samples from patients with DLBCL and matched normal tissue. We identified recurrent mutations in genes that are well known to be functionally relevant in DLBCL, including MYD88, CARD11, EZH2, and CREBBP. We also identified somatic mutations in genes for which a functional role in DLBCL has not been previously suspected. These genes include MEF2B, MLL2, BTG1, GNA13, ACTB, P2RY8, PCLO, and TNFRSF14. Further, we show that BCL2 mutations commonly occur in patients with BCL2/IgH rearrangements as a result of somatic hypermutation normally occurring at the IgH locus. The BCL2 point mutations are primarily synonymous, and likely caused by activation-induced cytidine deaminase–mediated somatic hypermutation, as shown by comprehensive analysis of enrichment of mutations in WRCY target motifs. Those nonsynonymous mutations that are observed tend to be found outside of the functionally important BH domains of the protein, suggesting that strong negative selection against BCL2 loss-of-function mutations is at play. Last, by using an algorithm designed to identify likely functionally relevant but infrequent mutations, we identify KRAS, BRAF, and NOTCH1 as likely drivers of DLBCL pathogenesis in some patients. Our data provide an unbiased view of the landscape of mutations in DLBCL, and this in turn may point toward new therapeutic strategies for the disease.


Nature | 2012

Reconstructing Native American population history.

David Reich; Nick Patterson; Desmond D. Campbell; Arti Tandon; Stéphane Mazières; Nicolas Ray; María Victoria Parra; Winston Rojas; Constanza Duque; Natalia Mesa; Luis F. García; Omar Triana; Silvia Blair; Amanda Maestre; Juan C. Dib; Claudio M. Bravi; Graciela Bailliet; Daniel Corach; Tábita Hünemeier; Maria-Cátira Bortolini; Francisco M. Salzano; Maria Luiza Petzl-Erler; Victor Acuña-Alonzo; Carlos A. Aguilar-Salinas; Samuel Canizales-Quinteros; Teresa Tusié-Luna; Laura Riba; Maricela Rodríguez-Cruz; Mardia Lopez-Alarcón; Ramón Coral-Vazquez

The peopling of the Americas has been the subject of extensive genetic, archaeological and linguistic research; however, central questions remain unresolved. One contentious issue is whether the settlement occurred by means of a single migration or multiple streams of migration from Siberia. The pattern of dispersals within the Americas is also poorly understood. To address these questions at a higher resolution than was previously possible, we assembled data from 52 Native American and 17 Siberian groups genotyped at 364,470 single nucleotide polymorphisms. Here we show that Native Americans descend from at least three streams of Asian gene flow. Most descend entirely from a single ancestral population that we call ‘First American’. However, speakers of Eskimo–Aleut languages from the Arctic inherit almost half their ancestry from a second stream of Asian gene flow, and the Na-Dene-speaking Chipewyan from Canada inherit roughly one-tenth of their ancestry from a third stream. We show that the initial peopling followed a southward expansion facilitated by the coast, with sequential population splits and little gene flow after divergence, especially in South America. A major exception is in Chibchan speakers on both sides of the Panama isthmus, who have ancestry from both North and South America.


Science | 2014

The genetics of Mexico recapitulates Native American substructure and affects biomedical traits

Andres Moreno-Estrada; Christopher R. Gignoux; Juan Carlos Fernández-López; Fouad Zakharia; Martin Sikora; Alejandra V. Contreras; Victor Acuña-Alonzo; Karla Sandoval; Celeste Eng; Sandra Romero-Hidalgo; Patricia Ortiz-Tello; Victoria Robles; Eimear E. Kenny; Ismael Nuño-Arana; Rodrigo Barquera-Lozano; Gastón Macín-Pérez; Julio Granados-Arriola; Scott Huntsman; Joshua M. Galanter; Marc Via; Jean G. Ford; Rocio Chapela; William Rodriguez-Cintron; Jose R. Rodriguez-Santana; Isabelle Romieu; Juan José Luis Sienra-Monge; Blanca Estela del Río Navarro; Stephanie J. London; Andres Ruiz-Linares; Rodrigo García-Herrera

The population structure of Native Mexicans The genetics of indigenous Mexicans exhibit substantial geographical structure, some as divergent from each other as are existing populations of Europeans and Asians. By performing genome-wide analyses on Native Mexicans from differing populations, Moreno-Estrada et al. successfully recapitulated the pre-Columbian substructure of Mexico. This ancestral structure is evident among cosmopolitan Mexicans and is correlated with subcontinental origins and medically relevant aspects of lung function. These findings exemplify the importance of understanding the genetic contributions of admixed individuals. Science, this issue p. 1280 Indigenous and cosmopolitan Mexican populations are highly structured with genetic variation of medical relevance. Mexico harbors great cultural and ethnic diversity, yet fine-scale patterns of human genome-wide variation from this region remain largely uncharacterized. We studied genomic variation within Mexico from over 1000 individuals representing 20 indigenous and 11 mestizo populations. We found striking genetic stratification among indigenous populations within Mexico at varying degrees of geographic isolation. Some groups were as differentiated as Europeans are from East Asians. Pre-Columbian genetic substructure is recapitulated in the indigenous ancestry of admixed mestizo individuals across the country. Furthermore, two independently phenotyped cohorts of Mexicans and Mexican Americans showed a significant association between subcontinental ancestry and lung function. Thus, accounting for fine-scale ancestry patterns is critical for medical and population genetic studies within Mexico, in Mexican-descent populations, and likely in many other populations worldwide.


PLOS Genetics | 2012

Development of a panel of genome-wide ancestry informative markers to study admixture throughout the americas

Joshua M. Galanter; Juan Carlos Fernández-López; Christopher R. Gignoux; Jill S. Barnholtz-Sloan; Ceres Fernandez-Rozadilla; Marc Via; Alfredo Hidalgo-Miranda; Alejandra V. Contreras; Laura Uribe Figueroa; Paola Raska; Gerardo Jimenez-Sanchez; Irma Silva Zolezzi; M.D. Torres; Clara Ruiz–Ponte; Y. Ruiz; Antonio Salas; Elizabeth A. Nguyen; Celeste Eng; Lisbeth Borjas; William Zabala; Guillermo Barreto; Fernando Rondóo González; A. Ibarra; Patricia Taboada; L. Porras; Fabián Moreno; Abigail W. Bigham; Gerardo Gutiérrez; Tom D. Brutsaert; Fabiola León-Velarde

Most individuals throughout the Americas are admixed descendants of Native American, European, and African ancestors. Complex historical factors have resulted in varying proportions of ancestral contributions between individuals within and among ethnic groups. We developed a panel of 446 ancestry informative markers (AIMs) optimized to estimate ancestral proportions in individuals and populations throughout Latin America. We used genome-wide data from 953 individuals from diverse African, European, and Native American populations to select AIMs optimized for each of the three main continental populations that form the basis of modern Latin American populations. We selected markers on the basis of locus-specific branch length to be informative, well distributed throughout the genome, capable of being genotyped on widely available commercial platforms, and applicable throughout the Americas by minimizing within-continent heterogeneity. We then validated the panel in samples from four admixed populations by comparing ancestry estimates based on the AIMs panel to estimates based on genome-wide association study (GWAS) data. The panel provided balanced discriminatory power among the three ancestral populations and accurate estimates of individual ancestry proportions (R2>0.9 for ancestral components with significant between-subject variance). Finally, we genotyped samples from 18 populations from Latin America using the AIMs panel and estimated variability in ancestry within and between these populations. This panel and its reference genotype information will be useful resources to explore population history of admixture in Latin America and to correct for the potential effects of population stratification in admixed samples in the region.


JAMA | 2014

Association of a Low-Frequency Variant in HNF1A With Type 2 Diabetes in a Latino Population

Karol Estrada; Ingvild Aukrust; Lise Bjørkhaug; Noël P. Burtt; Josep M. Mercader; Humberto García-Ortiz; Alicia Huerta-Chagoya; Hortensia Moreno-Macías; Geoffrey A. Walford; Jason Flannick; Amy Williams; María J. Gómez-Vázquez; Juan Carlos Fernández-López; Angélica Martínez-Hernández; Silvia Jiménez-Morales; Federico Centeno-Cruz; Elvia Mendoza-Caamal; Cristina Revilla-Monsalve; Sergio Islas-Andrade; Emilio J. Córdova; Xavier Soberón; María Elena González-Villalpando; E. Henderson; Lynne R. Wilkens; Loic Le Marchand; Olimpia Arellano-Campos; María Luisa Ordóñez-Sánchez; Maribel Rodríguez-Torres; Rosario Rodríguez-Guillén; Laura Riba

IMPORTANCE Latino populations have one of the highest prevalences of type 2 diabetes worldwide. OBJECTIVES To investigate the association between rare protein-coding genetic variants and prevalence of type 2 diabetes in a large Latino population and to explore potential molecular and physiological mechanisms for the observed relationships. DESIGN, SETTING, AND PARTICIPANTS Whole-exome sequencing was performed on DNA samples from 3756 Mexican and US Latino individuals (1794 with type 2 diabetes and 1962 without diabetes) recruited from 1993 to 2013. One variant was further tested for allele frequency and association with type 2 diabetes in large multiethnic data sets of 14,276 participants and characterized in experimental assays. MAIN OUTCOME AND MEASURES Prevalence of type 2 diabetes. Secondary outcomes included age of onset, body mass index, and effect on protein function. RESULTS A single rare missense variant (c.1522G>A [p.E508K]) was associated with type 2 diabetes prevalence (odds ratio [OR], 5.48; 95% CI, 2.83-10.61; P = 4.4 × 10(-7)) in hepatocyte nuclear factor 1-α (HNF1A), the gene responsible for maturity onset diabetes of the young type 3 (MODY3). This variant was observed in 0.36% of participants without type 2 diabetes and 2.1% of participants with it. In multiethnic replication data sets, the p.E508K variant was seen only in Latino patients (n = 1443 with type 2 diabetes and 1673 without it) and was associated with type 2 diabetes (OR, 4.16; 95% CI, 1.75-9.92; P = .0013). In experimental assays, HNF-1A protein encoding the p.E508K mutant demonstrated reduced transactivation activity of its target promoter compared with a wild-type protein. In our data, carriers and noncarriers of the p.E508K mutation with type 2 diabetes had no significant differences in compared clinical characteristics, including age at onset. The mean (SD) age for carriers was 45.3 years (11.2) vs 47.5 years (11.5) for noncarriers (P = .49) and the mean (SD) BMI for carriers was 28.2 (5.5) vs 29.3 (5.3) for noncarriers (P = .19). CONCLUSIONS AND RELEVANCE Using whole-exome sequencing, we identified a single low-frequency variant in the MODY3-causing gene HNF1A that is associated with type 2 diabetes in Latino populations and may affect protein function. This finding may have implications for screening and therapeutic modification in this population, but additional studies are required.


PLOS ONE | 2014

Exploring the Distribution of Genetic Markers of Pharmacogenomics Relevance in Brazilian and Mexican Populations

Vania Bonifaz-Peña; Alejandra V. Contreras; Claudio J. Struchiner; Rosimeire Aparecida Roela; Tatiane K. Furuya-Mazzotti; Roger Chammas; Claudia Rangel-Escareño; Laura Uribe-Figueroa; María José Gómez-Vázquez; Howard L. McLeod; Alfredo Hidalgo-Miranda; Esteban J. Parra; Juan Carlos Fernández-López; Guilherme Suarez-Kurtz

Studies of pharmacogenomics-related traits are increasingly being performed to identify loci that affect either drug response or susceptibility to adverse drug reactions. However, the effect of the polymorphisms can differ in magnitude or be absent depending on the population being assessed. We used the Affymetrix Drug Metabolizing Enzymes and Transporters (DMET) Plus array to characterize the distribution of polymorphisms of pharmacogenetics and pharmacogenomics (PGx) relevance in two samples from the most populous Latin American countries, Brazil and Mexico. The sample from Brazil included 268 individuals from the southeastern state of Rio de Janeiro, and was stratified into census categories. The sample from Mexico comprised 45 Native American Zapotecas and 224 self-identified Mestizo individuals from 5 states located in geographically distant regions in Mexico. We evaluated the admixture proportions in the Brazilian and Mexican samples using a panel of Ancestry Informative Markers extracted from the DMET array, which was validated with genome-wide data. A substantial variation in ancestral proportions across census categories in Brazil, and geographic regions in Mexico was identified. We evaluated the extent of genetic differentiation (measured as FST values) of the genetic markers of the DMET Plus array between the relevant parental populations. Although the average levels of genetic differentiation are low, there is a long tail of markers showing large frequency differences, including markers located in genes belonging to the Cytochrome P450, Solute Carrier (SLC) and UDP-glucuronyltransferase (UGT) families as well as other genes of PGx relevance such as ABCC8, ADH1A, CHST3, PON1, PPARD, PPARG, and VKORC1. We show how differences in admixture history may have an important impact in the distribution of allele and genotype frequencies at the population level.


Pharmacogenomics | 2011

Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos

Francisco Sanchez-Giron; Beatriz Villegas-Torres; Karla Jaramillo-Villafuerte; Irma Silva-Zolezzi; Juan Carlos Fernández-López; Gerardo Jimenez-Sanchez; Alessandra Carnevale

UNLABELLED Prospective screening for HLA-B*5701 decreases or abolishes abacavir hypersensitivity reaction. In Caucasians, the HLA complex protein 5 gene (HCP5) rs2395029(G) allele is in complete linkage disequilibrium (LD) with HLA-B*5701 (r(2) = 1). AIM To assess the frequency of HLA-B*5701 and its LD with HCP5 rs2395029(G) allele, to extend our knowledge of genetic variants that are of critical relevance for the development of pharmacogenetics in Mexico. MATERIALS & METHODS We genotyped 300 Mexican Mestizos from the Mexican Genome Diversity Project. HLA-B*5701 genotyping was performed using a DNA sequencing method. HCP5 rs2395029 was genotyped using a custom TaqMan(®) SNP genotyping assay and confirmed by direct sequencing. Genotypes for 14 SNPs in the HCP5 region were retrieved from the Mexican Genome Diversity Project database for LD analysis. RESULTS HLA-B*5701 carrier frequency was 2% and the allelic frequency was 0.010. Haplotype analysis revealed that HLA-B*5701 and the HCP5 rs2395029(G) allele are in complete LD (r(2) = 1) in this Mexican Mestizos sample. CONCLUSION It is feasible to have a pharmacogenetic program based on HCP5 rs2395029 genotyping as a screening tool with confirmation of HLA-B*5701 carriage by sequenciation, to prevent abacavir hypersensitivity reaction in Mexican patients before initiating abacavir therapy.


intelligent systems in molecular biology | 2007

GPDTI: A Genetic Programming Decision Tree Induction method to find epistatic effects in common complex diseases

Jesús K. Estrada-Gil; Juan Carlos Fernández-López; Enrique Hernández-Lemus; Irma Silva-Zolezzi; Alfredo Hidalgo-Miranda; Gerardo Jimenez-Sanchez; Edgar E. Vallejo-Clemente

MOTIVATION The identification of risk-associated genetic variants in common diseases remains a challenge to the biomedical research community. It has been suggested that common statistical approaches that exclusively measure main effects are often unable to detect interactions between some of these variants. Detecting and interpreting interactions is a challenging open problem from the statistical and computational perspectives. Methods in computing science may improve our understanding on the mechanisms of genetic disease by detecting interactions even in the presence of very low heritabilities. RESULTS We have implemented a method using Genetic Programming that is able to induce a Decision Tree to detect interactions in genetic variants. This method has a cross-validation strategy for estimating classification and prediction errors and tests for consistencies in the results. To have better estimates, a new consistency measure that takes into account interactions and can be used in a genetic programming environment is proposed. This method detected five different interaction models with heritabilities as low as 0.008 and with prediction errors similar to the generated errors. AVAILABILITY Information on the generated data sets and executable code is available upon request.

Collaboration


Dive into the Juan Carlos Fernández-López's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alejandra V. Contreras

National Autonomous University of Mexico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Enrique Hernández-Lemus

National Autonomous University of Mexico

View shared research outputs
Researchain Logo
Decentralizing Knowledge